Yue TAO, MD

CONTACT

Lead Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.
•Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.
•Achieved PASI 75 response at the end of the induction period.
•Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.
•Complete electronic medical record data available for extraction.

•Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.
•Irregular maintenance treatment pattern, or substantial missing data.
•Use of other targeted biologic agents or small molecule drugs during the maintenance period.
•Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.
•Participation in other interventional clinical trials that may confound efficacy assessment.